JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Scope & Guideline

Enhancing knowledge for a healthier heart.

Introduction

Immerse yourself in the scholarly insights of JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1074-2484
PublisherSAGE PUBLICATIONS INC
Support Open AccessYes
CountryUnited Kingdom
TypeJournal
Convergefrom 1996 to 2024
AbbreviationJ CARDIOVASC PHARM T / J. Cardiovasc. Pharmacol. Ther.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2455 TELLER RD, THOUSAND OAKS, CA 91320

Aims and Scopes

The Journal of Cardiovascular Pharmacology and Therapeutics aims to advance knowledge in the field of cardiovascular pharmacotherapy. It publishes research focusing on the development, efficacy, and safety of pharmacological treatments for cardiovascular conditions, as well as innovative therapeutic approaches and their clinical implications.
  1. Pharmacological Interventions for Cardiovascular Diseases:
    The journal emphasizes studies on various pharmacological agents used to treat cardiovascular diseases, including novel therapies and existing medications, assessing their safety and efficacy.
  2. Clinical Outcomes and Real-World Evidence:
    Research that evaluates the outcomes of cardiovascular treatments in clinical practice, including observational studies and real-world data analyses, is a core focus.
  3. Mechanistic Studies in Cardiovascular Pharmacology:
    Investigations into the underlying mechanisms of action of cardiovascular drugs, including molecular and cellular pathways, are regularly featured.
  4. Therapeutic Innovations and Trials:
    The journal places a strong emphasis on clinical trials and innovative therapeutic approaches, including combination therapies and new drug formulations.
  5. Impact of Comorbidities on Cardiovascular Treatment:
    Research examining how comorbid conditions (e.g., diabetes, chronic kidney disease) affect cardiovascular treatment outcomes is a prominent theme.
The Journal of Cardiovascular Pharmacology and Therapeutics has increasingly embraced new and emerging themes in cardiovascular research. Recent publications indicate a shift towards exploring innovative therapies and addressing contemporary challenges in cardiovascular care.
  1. SGLT2 Inhibitors and Heart Failure:
    There is a growing focus on the role of SGLT2 inhibitors in treating heart failure, especially in patients with diabetes, highlighting their multifaceted benefits.
  2. Personalized Medicine and Genotyping:
    Emerging studies emphasize the importance of personalized medicine approaches, including genotyping for anticoagulant therapy, reflecting a trend towards individualized treatment strategies.
  3. Impact of Lifestyle Factors on Cardiovascular Health:
    Research exploring the effects of lifestyle factors—such as diet, physical activity, and smoking—on cardiovascular health and treatment outcomes is gaining traction.
  4. Cardiovascular Effects of Novel Therapies:
    An increased interest in the cardiovascular implications of non-cardiovascular drugs and therapies, including those used in cancer treatment, is evident in recent publications.
  5. Integrative Approaches to Cardiovascular Care:
    There is a notable trend towards integrative strategies combining pharmacological and non-pharmacological interventions, emphasizing holistic patient management.

Declining or Waning

While the journal has consistently focused on cardiovascular pharmacotherapy, certain themes have seen a decline in publication frequency or relevance. These waning scopes may reflect shifting research priorities or advancements in treatment paradigms.
  1. Traditional Antihypertensive Agents:
    Research focusing solely on traditional antihypertensive medications has decreased, as newer agents and combination therapies are gaining prominence.
  2. Static Observational Studies:
    The prevalence of static observational studies without innovative designs or significant clinical implications appears to be declining, as the journal increasingly favors studies with robust methodologies and real-world applications.
  3. Basic Science without Clinical Relevance:
    Papers focusing solely on basic science aspects of cardiovascular pharmacology, lacking direct clinical relevance or application, have been published less frequently.

Similar Journals

Journal of the Practice of Cardiovascular Sciences

Innovating Solutions in Cardiovascular Health
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2395-5414Frequency: 3 issues/year

Journal of the Practice of Cardiovascular Sciences, published by Wolters Kluwer Medknow Publications, is an esteemed Open Access journal dedicated to advancing knowledge in the field of cardiovascular health. With its ISSN 2395-5414 and E-ISSN 2454-2830, the journal serves as a vital platform for researchers, healthcare professionals, and students to disseminate and access high-quality studies, innovations, and practical applications related to cardiovascular sciences. Established in 2015 as an Open Access journal, it promotes widespread sharing of insights to enhance cardiovascular practices and address contemporary challenges in the field. As part of a reputable publishing group, the journal is poised for growth and impact, contributing significantly to the ongoing dialogue in cardiovascular research and clinical practice.

CARDIOVASCULAR DRUGS AND THERAPY

Uncovering the latest in cardiovascular drug advancements.
Publisher: SPRINGERISSN: 0920-3206Frequency: 6 issues/year

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.

Cardiovascular Diagnosis and Therapy

Elevating Standards in Cardiovascular Medicine and Research
Publisher: AME PUBLISHING COMPANYISSN: 2223-3652Frequency: 6 issues/year

Cardiovascular Diagnosis and Therapy, an esteemed journal in the field of Cardiology and Cardiovascular Medicine, is published by AME PUBLISHING COMPANY, based in Hong Kong, China. With an ISSN of 2223-3652 and an E-ISSN of 2223-3660, this open-access journal aims to present cutting-edge research that significantly advances diagnostic and therapeutic practices in cardiovascular health. Recognized for its impact, it holds a 2023 category quartile ranking of Q2 and is positioned at rank #124 out of 387 in Scopus, reflecting its noteworthy contribution to medical literature with a percentile of 68th. The journal welcomes contributions that span various aspects of cardiovascular research, including clinical trials, epidemiological studies, and innovative therapeutic approaches, making it a vital resource for researchers, practitioners, and students alike, committed to improving cardiovascular care.

Expert Review of Clinical Pharmacology

Elevating the standards of clinical pharmacology for better health.
Publisher: TAYLOR & FRANCIS LTDISSN: 1751-2433Frequency: 12 issues/year

Expert Review of Clinical Pharmacology, published by TAYLOR & FRANCIS LTD, is a leading peer-reviewed journal dedicated to the field of clinical pharmacology, with a strong focus on the development and application of pharmacological therapies in patient care. Boasting an impressive impact, the journal ranks in the first quartile across multiple categories including Medicine (miscellaneous), Pharmacology (medical), and Pharmacology, Toxicology and Pharmaceutics (miscellaneous), reflecting its influential position within the scientific community. With a Scopus ranking of #6 in General Pharmacology, Toxicology and Pharmaceutics, the journal also achieves a commendable 93rd percentile, further emphasizing its importance as a resource for researchers and clinicians alike. As it continues to publish innovative reviews and research articles from 2008 until 2024, the Expert Review of Clinical Pharmacology plays an essential role in advancing knowledge, improving clinical practice, and fostering collaboration among experts in pharmacology, thereby driving forward the field's evolution towards better patient outcomes.

CIRCULATION

Leading the Charge in Heart Health Research.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0009-7322Frequency: 50 issues/year

CIRCULATION is a premier journal in the field of cardiology and cardiovascular medicine, published by Lippincott Williams & Wilkins. With a distinguished history dating back to 1950, the journal has consistently been at the forefront of critical research, showcasing significant advancements and discoveries in cardiovascular health. It holds a remarkable Q1 ranking in both the fields of Cardiology and Physiology (medical) according to the 2023 category quartiles, demonstrating its influential role among the top publications in these disciplines. With an impressive Scopus ranking, placed 3rd out of 387 in Cardiology and 2nd out of 113 in Physiology, CIRCULATION is essential reading for researchers, practitioners, and students passionate about advancing their understanding of heart health and related medical sciences. Although the journal is not open access, it continues to foster scholarly exchange and innovation in cardiovascular research, making it an indispensable resource for quality insights and groundbreaking studies.

Archives of Cardiovascular Diseases

Unlocking new horizons in cardiovascular health and treatment.
Publisher: ELSEVIER MASSON, CORP OFFISSN: 1875-2136Frequency: 12 issues/year

The Archives of Cardiovascular Diseases, published by Elsevier Masson, stands as a leading journal in the field of cardiology and cardiovascular medicine, with an impressive impact factor that underscores its relevance and influence. This esteemed journal, recognized in the Q2 category for both cardiology and miscellaneous medicine, aims to disseminate groundbreaking research, innovative methodologies, and clinical advancements that can shape the future of cardiovascular health. With its diverse array of open access options, researchers and students alike have the ability to engage with high-quality content, ensuring that cutting-edge findings are accessible globally. Since its inception in 2008, the journal has actively contributed to the advancement of knowledge in cardiovascular diseases, fostering collaboration among clinicians, researchers, and educators. Headquartered in Paris, France, Archives of Cardiovascular Diseases remains committed to enhancing our understanding of cardiovascular health and improving patient outcomes worldwide.

Nepalese Heart Journal

Transforming Heart Health Through Research
Publisher: CARDIAC SOC NEPALISSN: 2091-2978Frequency: 1 issue/year

Nepalese Heart Journal, published by the CARDIAC SOC NEPAL, serves as a premier platform for disseminating knowledge in the field of cardiology and cardiovascular health. With an ISSN of 2091-2978, this journal aims to bridge the gap between researchers, clinicians, and academicians by presenting high-quality, peer-reviewed articles that address clinical practices, innovative research, and emerging trends in heart disease management, especially within the context of Nepal and the surrounding region. Although it operates under a traditional publishing model, its commitment to excellence aids in reinforcing the scientific discourse in an area critical to public health. The journal is a valuable resource for professionals and students alike who are focused on advancing their understanding of cardiology and its implications for health policy and practice. Exploring the intersections of local challenges and global advancements in heart health, the Nepalese Heart Journal is poised to contribute meaningfully to the evolving landscape of cardiovascular research.

American Journal of Preventive Cardiology

Your Gateway to Cutting-Edge Cardiology Research.
Publisher: ELSEVIERISSN: 2666-6677Frequency: 4 issues/year

American Journal of Preventive Cardiology, published by ELSEVIER, is a premier Open Access journal that has been making significant strides in the field of cardiology since its inception in 2020. With an impressive impact factor and recognized as a Q1 journal in the Cardiology and Cardiovascular Medicine category as of 2023, it ranks 77th out of 387 in the Scopus database, placing it in the 80th percentile of its field. The journal aims to promote the latest research and practices in preventive cardiology, addressing the global burden of cardiovascular diseases through a combination of innovative findings and practical applications. With the advantage of Open Access, all published articles are readily available to researchers, professionals, and students worldwide, fostering a broad dissemination of knowledge and encouraging collaboration across disciplines. Based in Amsterdam, Netherlands, the journal is committed to advancing the science and prevention of heart disease, making it an essential resource for those dedicated to improving cardiovascular health.

Cardiology in Review

Pioneering reviews that shape cardiovascular care.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1061-5377Frequency: 6 issues/year

Cardiology in Review, published by Lippincott Williams & Wilkins, is a prominent journal focused on advancing the field of cardiology and cardiovascular medicine. With a history of publication spanning from 1995 to 2024, the journal serves as an essential resource for researchers, healthcare professionals, and students alike, offering in-depth reviews and analyses on the latest developments, clinical practices, and research findings in cardiology. Despite being a traditional print journal, it maintains a commendable Q2 ranking in both cardiology and miscellaneous medicine categories as of 2023, reflecting its influence and rigor in the academic community, with a Scopus rank of #132 out of 387 in its field, placing it in the 66th percentile. The journal aims to bridge the gap between clinical practice and emerging research, promoting a deeper understanding and integration of innovative strategies in cardiovascular care. With its commitment to high-quality scholarship, Cardiology in Review remains a vital conduit for knowledge and dialogue within the evolving landscape of cardiovascular health.

Cardiovascular Therapeutics

Unlocking Innovations in Cardiovascular Medicine
Publisher: WILEY-HINDAWIISSN: 1755-5914Frequency: 1 issue/year

Cardiovascular Therapeutics is a renowned Open Access journal, published by WILEY-HINDAWI, that has been at the forefront of advancing knowledge in the field of cardiology and cardiovascular medicine since its establishment. With a strong commitment to disseminating high-quality research, the journal has successfully positioned itself within the Q2 quartile in multiple categories, including Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), and Pharmacology. The journal is indexed in Scopus, achieving impressive rankings, such as #95 out of 387 in Cardiology, and #87 out of 272 in Medical Pharmacology. Situated in the United Kingdom, Cardiovascular Therapeutics embraces an Open Access model since 2019, ensuring that groundbreaking research is accessible to researchers, practitioners, and students across the globe. The journal is dedicated to publishing original research articles, reviews, and clinical studies that contribute to the understanding and treatment of cardiovascular diseases, making it an essential resource for those invested in improving patient outcomes and advancing therapeutic strategies in this vital area of medicine.